JOP20210317A1 - مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان - Google Patents

مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان

Info

Publication number
JOP20210317A1
JOP20210317A1 JOP/2021/0317A JOP20210317A JOP20210317A1 JO P20210317 A1 JOP20210317 A1 JO P20210317A1 JO P20210317 A JOP20210317 A JO P20210317A JO P20210317 A1 JOP20210317 A1 JO P20210317A1
Authority
JO
Jordan
Prior art keywords
mat2a
methods
treating cancer
inhibitors
compounds
Prior art date
Application number
JOP/2021/0317A
Other languages
English (en)
Inventor
Jeremy M Travins
Zhihua Sui
Mingzong Li
Samuel K Reznik
Zenon D Konteatis
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of JOP20210317A1 publication Critical patent/JOP20210317A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات لها الصيغة I، والصيغة II، وأملاحها المقبولة صيدليًا، مماثلات كيميائية، و/أو نظائر على النحو الموصوف في الكشف. تكون المركبات عبارةً عن مثبطات من صورة ميثيونين أدينوزيل ترانسفيراز المتماثلة 2A (MAT2A). كما يتعلق الاختراع الحالي بتوفير تركيبات صيدلية وطرق استخدام المركبات لعلاج سرطانات، بما في ذلك بعض السرطانات التي يتم فيها حذف الجين المرمِّز لميثيل ثيو أدينوزين فوسفوريلاز (MTAP).
JOP/2021/0317A 2019-05-31 2020-05-29 مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان JOP20210317A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962855395P 2019-05-31 2019-05-31
PCT/US2020/035036 WO2020243376A1 (en) 2019-05-31 2020-05-29 Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Publications (1)

Publication Number Publication Date
JOP20210317A1 true JOP20210317A1 (ar) 2023-01-30

Family

ID=72179154

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0317A JOP20210317A1 (ar) 2019-05-31 2020-05-29 مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان

Country Status (16)

Country Link
US (1) US20220251081A1 (ar)
EP (1) EP3976611A1 (ar)
JP (1) JP2022534989A (ar)
AR (1) AR119046A1 (ar)
AU (1) AU2020284018A1 (ar)
BR (1) BR112021023825A2 (ar)
CA (1) CA3142340A1 (ar)
CO (1) CO2021017981A2 (ar)
CR (1) CR20210670A (ar)
IL (1) IL288395A (ar)
JO (1) JOP20210317A1 (ar)
MA (1) MA56050A (ar)
PE (1) PE20220387A1 (ar)
SG (1) SG11202112952SA (ar)
TW (1) TW202110841A (ar)
WO (1) WO2020243376A1 (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022052924A1 (zh) * 2020-09-11 2022-03-17 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
CN115960099A (zh) * 2020-09-24 2023-04-14 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
US11912668B2 (en) 2020-11-18 2024-02-27 Deciphera Pharmaceuticals, Llc GCN2 and perk kinase inhibitors and methods of use thereof
JP2024502097A (ja) * 2020-12-31 2024-01-17 南京再明医薬有限公司 三環式化合物とその用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2022228515A1 (zh) * 2021-04-30 2022-11-03 赛诺哈勃药业（成都）有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
WO2023083210A1 (zh) * 2021-11-09 2023-05-19 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
TW202333696A (zh) * 2022-01-26 2023-09-01 大陸商勤浩醫藥(蘇州)有限公司 用於治療ｍｔａｐ缺失型癌症的甲硫氨酸腺苷轉移酶２ａ抑制劑
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
WO2024080788A1 (ko) * 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도
CN116239541B (zh) * 2023-05-11 2023-07-21 英矽智能科技(上海)有限公司 N-苯基-2-氧代喹唑啉类化合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
AU9378401A (en) * 2000-08-31 2002-03-13 Hoffmann La Roche 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
AU2008266883B2 (en) 2007-06-20 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CN111936499B (zh) * 2018-03-30 2023-09-19 法国施维雅药厂 Mat2a的杂二环抑制剂和用于治疗癌症的方法

Also Published As

Publication number Publication date
CA3142340A1 (en) 2020-12-03
MA56050A (fr) 2022-04-06
AU2020284018A1 (en) 2022-01-27
EP3976611A1 (en) 2022-04-06
IL288395A (en) 2022-01-01
AR119046A1 (es) 2021-11-17
TW202110841A (zh) 2021-03-16
PE20220387A1 (es) 2022-03-18
CO2021017981A2 (es) 2022-04-19
JP2022534989A (ja) 2022-08-04
CR20210670A (es) 2022-02-11
US20220251081A1 (en) 2022-08-11
SG11202112952SA (en) 2021-12-30
WO2020243376A1 (en) 2020-12-03
BR112021023825A2 (pt) 2022-02-08

Similar Documents

Publication Publication Date Title
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
PH12020551507A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
CR20210409A (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12021551274A1 (en) 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
PH12021550995A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
CR20200441A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
MX2020012376A (es) Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).